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N-Bromoacetyl-2-iodo-S-methoxytryptamine (BIM), a ovel derivative of the biologically active melatonin analog, 24odomelatonin, was prepared 
and used to identify melatonin binding proteins in rat brain synaptosomcs. Incubation of the synaptosomcs with BIM resulted in a time and wncen- 
trntion dependent, irreversible inhibition of 2-raSI]iodomelatonin binding. In parallel, the radioactive form of BIM, N-bromoacetyI-2-~aSI]iodo-4- 
methoxytryptamine (rzsI]BIM) became incorporated into the synaptosomcs. The incorporation of PzsI]BIM was inhibited by BIM, 2-iodomela- 
tonin and mclatonin but not by S-mcthoxytryptamine or N-a&y1 serotonin. rzSI]BIM became covalently attached to three polypeptides with appar- 
cnt molecular weight values of 92, 55 and 45 kDa; the labeling of all three proteins was markedly inhibited by mclatonin. These results indicate 
that the 92.55 and 45 kDa polypeptides arc melatonin binding proteins. 
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1. INTRODUCTION 
The nocturnal production and secretion of melatonin 
by the pineal gland of vertebrates provides a signal 
which coordinates the neuroendocrine system with the 
environmental lighting cycles [l]. The use of 2-[“‘I]io- 
domelatonin ([‘251]me1atonin), a potent melatonin 
analog enabled the characterization and quantitation of 
low (Kd ca. 40-70 nM) and high affinity (& 20-40 PM) 
melatonin binding sites in synaptosomes and slices from 
the brains of various species [2-61, and enabled the 
elucidation of some of their properties such as: their 
modulation by guanyl nucleotides [7] and cations [8], 
diurnal variations in binding site density and their 
regulation by melatonin, photoperiod and sex steroids 
[3,10-IS] and determination of the apparent molecular 
mass of melatonin receptors by target size analysis [9], 
but the molecular structure of these sites has not been 
elucidated. We have developed a novel, chemically re- 
active, [lzSI]melatonin derivative, N-bromoacetyl- 
2-[‘2SI]iodo-5-methoxytryptamine ([‘2sI]131M), and 
report here on the identification of melatonin binding 
proteins using this compound as an affinity label. 
2. MATERIALS AND METHODS 
Preparation of I\‘-bromoacetyl-2-iodo-S-mcthoxytryptamine 
(kM). To a solution of S-mcthoxytryptamine in dimethylformemide 
containing 2 cquivalcnts of tricthylamine, 3 equivalents of 
BrCH2COCl wcrc added and the reaction was allowed to proceed at 
room tcmpcraturc in the dark for 60 niin. The pH was then brought 
to >7 with NaklC0~ and the mixture was left for another 20min and 
Corre~pandccrtcc orf iress: N. Zirapcl, The Gcorgc S. Wise Fxuky of 
Lift Scicnccs, Tel Aviv University, Tel Aviv 69978, Israel. 
then centrifuged (5 min lOOOO#g). The supernatant was evaporated 
to dryness and subjected to thin-layer chromatography (TLC) using 
silicagel plate with ethyl acetate as a solvent. The major product, 
bromoacetyl-5-methoxytryptamine (BM; Rr: = 0.6) was extracted with 
ethanol and iodinated according to Vakkuri et al. [16,17]. Briefly, BM 
in ethanol and KI (2 equivalents in H20) were added simultaneously 
to an Eppendorf tube precoated with Iodo-gen. After 1 min the 
products were extracted into chloroform and subjected to TLC using 
silicagel plates with ethyl acetate as a solvent. The major iodination 
product, BIM (R~=0.73) was extracted with ethanol. [‘251]BIM was 
prepared similarly, from BM and carrier-free Na”‘I (Amersham). 
BIM and [‘251]BIM co-migrated as single spots on silicagel TLC plates 
with ethylacetate (Fig. 1) or chloroform (not shown) as solvents. The 
spots were detected by iodine vapors, oxidation of the indolc moiety 
in UV light and autoradiography (Fig. 1). The chemical composition 
of BIM was verified by ‘H-nuclear magnetic resonance spectrum 
taken on a Bruker WM.360 NMR instrument in (CDC13 t CD30D) 
solution. ‘H (ppm relative to intcrnat TMS): 7.62s (H-l), 7.28dd 
(5=9,04 Hz, H-7), 6.95dd (J=2.9,0.4 Hz, H-4), 6.85dd (J=9.0, 2.9 
Hz, H-6), 6.70t (J=5.5 Hz, H-3’), 3.86s (S-OCHJ),’ 3.74s(H2-5’). 
3.58dt (J=6.9, 5.5 Hz, HZ-~‘), 2.821 (5=6.9 Hz, Hz-l’). 
2-[‘251]iodomclatonin ([‘2’l]mclatonin) and unlabeled t-iodo- 
melatonin were prepared by iodination of mclatonin as described 
[l&17). 2-[“‘l]iodomelatonin was diluted radioisotopically with 
unlabeled 2Godometatonin to yield a specific radioactivity of 20 
Ci/mmol. S-Methoxytryptamine, BrCH2COCI, melatonin and lodo- 
gen wctc purchased from Sigma, St. Louis, MO. 
Male rats of the CD strain (t-months-old), maintained on a daily 14 
h light:10 h darkness schedule (lights-on 05.00 h; cool white fhtores- 
cent illumination) at 24rtZ”C, were dccapitatcd between 09.00-I 1 .OO 
h and their brains were rapidly removed and suspended in 10 ml/g ice- 
cold 0.32 M sucrose. Crude synaptosomal pellets were prepared as 
described [2] and suspended in 2 vols of 50 niM Tris-HCt buffer, pH 
7.4 containing 5 mM CaC12. The following experiments were pcr- 
formed: 
(a) Aliquols of the synnptosomal preparations (0.4 mg prOtCin/ml; 
[IS]) wcrc incubated at 37OC with 10’.‘4-10-’ M BIM, for I-30 min. 
Mcmbrancs were then collcctcd byccntrifugation (lOtX@Xg, IOmin), 
and washed cxtcnsivcly by rcpcatcd cycles of rcsuspcnsion in the Tris 
buffer and ccntrifugation. The washed membranes wcrc resuspcndcd 
in the Tris buffer and the rcvcrsiblc equilibrium binding of 
[‘2.‘l]mclatonin was asscsscd: allquots of the mcmbrancs were in- 
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Fig. 1, Thin-layer chromarography (silicagel plate, in ethylacetate) of 
BIM. The plate was exposed to iodine vapors (a) and oxidation in UV 
light (b). (c) Autoradiogram of a chromatogram of [‘ZSI]BIM. 
cubated in triplicates with 50 nM [‘Lsl]melatonin at 37’C For 30 min 
in the absence or presence of unlabeled melatonin (50 PM). Mem- 
branes were then collected by vacuum Filtration on GFX filters as 
described (21 and the radioactivity determined. Specific binding was 
defined as that displaced by 50 !dcM melatonin. 
(b) Aliquots of the synaptosomal preparations were incubated with 
5 nM [‘*‘I]BIM (2100 CVmmol) in the absence or presence of various 
indoles (O-lo-’ M) For I-30 min at 37°C. Membranes were then col- 
lected by vacuum Filtration using GFX Filters and washed extensively 
with 3 x4 ml For 10 min at 4°C. The filters were assayed For sadioac- 
tivity using a gamma counter. 
(c) Synaptosomes were incubated with [‘2sl]BIM as in (b). The reac- 
tion was terminated by the addition of sodium-dodecyl sulfate (SDS) 
sample buffer (36 mM Tris-HCI. pH 6.8, 3% WVVOI SDS, 5% V/V 
2-mercaptoethanol and 10% v/v glycerol) and subjected to elec- 
trophoresis on 7070 polyacrylamide gels 1191 Followed by auto- 
radiography. 
3. RESULTS AND DISCUSSION 
Fig. 2A shows a time course of inhibition of [‘251]me- 
Iatonin binding, following preincubation of the rat 
brain synaptosomcs with BIM (1 PM) and extensive 
washing. Complete loss of the specific [‘2SI]meIatonin 
binding was observed within 30 min of incubation with 
BIM. The decrease followed apparent first order 
kinetics (k= 0.094*0.02 min-‘; Fig. 2A, inset), The 
time course of incorporation of [‘*‘I]BIM (5 nM) into 
the synaptosomes i shown in Fig. 2B. The incorpora- 
tion followed apparent first order kinetics 
(k=0.136&0.04 min-‘; Fig. 2B, inset). 
The concentration dependency of the BIM-mediated 
decrease in [‘2SI]meIatonin binding is shown in Fig, 3A. 
The percentage of inhibition of [‘*‘I]melatonin binding 
following 20 min incubations increased with increasing 
BIM concentration, approaching a plateau of ca. 5OVo 
inhibition between 5 and 100 nM. Further elevation of 
BIM concentration between 0.1-10 1cM resulted in a 
further concentration-dependent loss of [‘251]n~elatonin 
binding capacity, The biphasic concentration depend- 
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Fig. 2. (A) Effect of BIM treatment (I ,uIM; O-30 min) on the binding 
of 50 nM [‘2’l]melatonin to rat brain synaptosomes. Inset: The loss 
of [‘251]melatonin binding is plotted according to first order kinetics. 
Band B, are the binding at a specific time and zero, respectively. (B) 
Kinetics of the incorporation of [“SI]PIM (5 nM) into rat brain 
synaptosomes. Inset: Incorporation (6) is plotted according to first 
order kinetics. B and B’ are the amounts of radioactivity retained in 
the synaptosomes at a specific time and infinity, respectively. 
ency indicates that BIM forms two types of reversible 
complexes with melatonin binding sites, prior to the 
covalent modification: a high and a low affinity type, 
each accounting for 50% of the [‘2SI]melatonin bind- 
ing. The fact that the kinetics of inactivation by I PM 
BIM was not biphasic, suggests that the bromoacetyl 
group of BIM reacted with similar nucleophilic groups 
in the two types of complexes. In addition, the kinetic 
data indicated that the apparent first order rate con- 
stant of the incorporation of 5 nM [‘251]BIM was 
similar to the rate constant of the decrease in 
[‘2SI]melatonin binding produced by 1 PM BIM. This 
implies that the covalent modification is slow relative to 
the reversible association of BIM with the binding sites. 
The ability of various indole compounds to protect 
melatonin binding sites against the incorporation of 
[‘2SI]BIM (5 nM) during 10 min incubation periods was 
investigated (Fig. 3B). Unlabeled BIM prevented the in- 
corporation of [“‘I]BIM in a concentration-dependent 
manner, with 50% protection around 5 nM. This sug- 
gcsts that a 1: 1 complex of BIM with the ‘high affinity’ 
type of sites. Among the reversible competitors tudied, 
2-iodomelatonin and melatonin but not 5 mcthoxytryp- 
tarnine or N-acctyl scrotonin, significantly slowed down 
the incorporation of [12SI]BIM into the synaptosomes. 
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Fig. 3. (A) Concentration dependency of the decrease in binding of 50 nM [‘“sl]melatonin following treatment of synaptosomes with 0-1OpM BIM 
for 20 min. (9) Inhibition of incorporation of [‘ZSI]BIM (5 nM, 10 min) into rat synaptosomes by BIM (e), 2Godomelatonin (0). melatonin (A), 
N-acetyl serotonin (A) and 5 methoxytryptamine (0). The results are expressed as 100 (I - &I&) where B, and I&, are the amounts incorporated 
in the presence and absence of the indole, respectively. 
24odomelatonin was more potent than melatonin, 
which suits well the order of potency of these ligands at 
inhibiting reversible [‘251]melatonin bi ding in rat brain 
synaptosomes [2]. 
Following incubation of the rat brain synaptosomes 
with 5 nM [‘2sI]BIM for 30 min, the synaptosomal 
polypeptides were separated by SDS-polyacrylamide gel 
electrophoresis and the radiolabeled proteins were 
detected by autoradiography (Fig. 4). Only three 
polypeptides, with apparent molecular masses of 92, 55 
and 45 kDa repeatedly incorporated the label. An addi- 
tional labeled polypeptide with apparent molecular 
weight of 37 kDa was not always present. The 90 and 45 
kDa proteins were normally less abundant han the 55 
kDa protein. However, preliminary peptide-mapping 
studies indicated that the three proteins were distinct 
proteins rather than degradation products of the 92 
kDa protein. The labeling of all these proteins was 
markedly reduced in the presence of melatonin (10pM; 
Fig. 4) indicating that non-specific labeling under these 
conditions was very low. 
The results demonstrate the potency of BIM as a 
selective affinity label for melatonin binding proteins 
according to the following criteria: (1) formation of 
reversible complexes with the sites; (2) specific protec- 
tion against labeling by melatonin and 
2-iodomelatonin, in an order of potency corresponding 
to their relative affinity towards melatonin receptors; 
(3) exclusive labeling of proteins which also recognize 
melatonin. 
Interestingly, by using the technique of irradiation in- 
activation, the molecular mass of melatonin receptors 
in the chick retina was estimated to be ca. 44 kDa [9] 
which agrees well with one of the BIM target proteins 
found in our study; however, in the same study, the 
molecular mass of the receptor in the hamster 
hypothalamus was estimated at 30 kDa [9] suggesting 
an additional type of site in the rodent brain. Such a site 
might be the type which becomes inactivated by 
micromolecular concentrations of BIM and was not 
characterized here. It remains to be determined whether 
the 92, 55 and 45 kDa polypeptides represent melatonin 
receptor subunits or distinct subtypes. 
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Fig, 4. Autoradiographic identification of the synaptosomal proteins 
lab&d irreversibly with (““I]iHM (5 nM, 30 mia) in the absence and 
prcscncc of mclatonin (IO PM) as indicotcd. The proteins were rc- 
solved by polyacrylamidc gel clcctrophorcsis. fhc apparent molecular 
weight vitlucs of the lnbclcd proteins nre depicted. 
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